Skip to main content
MedPathMedPath Home
Clinical Trials/KCT0008650
KCT0008650
Recruiting
未知

A Multi-Center, Prospective, Open Label Clinical Trial to Evaluate Impact of Extended Electrocardiographic Monitoring Using MEMO Patch Plus in Patients with Acute Heart Failure

Asan Medical Center0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiseases of the circulatory system

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the circulatory system
Sponsor
Asan Medical Center
Enrollment
60
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\) Male or female adults aged 19 years or older at the time of informed consent
  • •2\) Participant who voluntarily agrees to participate and signs informed consent form in the study
  • •3\) Participant with Acute Heart Failure who is hospitalized\*
  • •\* It is defined as hospitalization or visiting ER (Emergency Room) due to worsening symptoms and signs of Heart Failure

Exclusion Criteria

  • •Any potential participant who meets any of the following criteria will be excluded from participating in the study.
  • •1\) Participant who does not have the ability to voluntarily decide on their decision to participate in the study
  • •2\) Participate who is admitted to ICU (Intensive Care Unit)
  • •3\) Participate diagnosed with the following the main type of arrhythmia on standard 12\-lead ECG evaluated for the first time after visiting the hospital
  • •\*Clinically Significant Arrhythmia is defined by the following items.
  • •A. Pause lasting more than 3 seconds
  • •B. High\-degree AV Block or Complete AV Block
  • •C. Atrial fibrillation/flutter
  • •D. Supraventricular tachycardia(including atrial tachycardia and paroxysmal ventricular tachycardia)
  • •E. Ventricular tachycardia

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Assessment of efficacy and safety of Lipid based Amphotericin B gel 0.1% (Amfy gel®) in patients with moderate to severe vulvovaginal candidiasis
CTRI/2014/02/004409Intas Pharmaceuticals Ltd60
Completed
Phase 4
A study to evaluate the efficacy and safety of vestige spirulina capsules for the immunity in healthy patients.
CTRI/2022/09/045585Vestige Marketing Pvt Ltd50
Completed
Not Applicable
A clinical trial to test the safety and effectiveness of Neuralzhein in management of memory loss related to age.Health Condition 1: F54- Psychological and behavioral factors associated with disorders or diseases classified elsewhere
CTRI/2019/08/020711exxus Laboratories DBA OPUS PHARMA
Completed
Phase 2
Clinical trial to study the Suitability for Consumption of Chyawanprakash in Controlled Type II Diabetic Patients.Health Condition 1: null- Type 2 Diabetes mellitus
CTRI/2013/04/003553Dabur Research Development Centre DRDC120
Recruiting
Phase 1
A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment)Hepatocellular CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
CTIS2023-508945-41-00Biocompatibles UK Limited107